Vaxcyte, Inc. (NASDAQ:PCVX) CEO Sells $199,679.28 in Stock

Vaxcyte, Inc. (NASDAQ:PCVX) CEO Grant Pickering sold 2,616 shares of the firm’s stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $76.33, for a total transaction of $199,679.28. Following the completion of the transaction, the chief executive officer now directly owns 143,438 shares in the company, valued at $10,948,622.54. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Grant Pickering also recently made the following trade(s):

• On Monday, June 24th, Grant Pickering sold 15,000 shares of Vaxcyte stock. The shares were sold at an average price of $75.64, for a total transaction of $1,134,600.00.
• On Monday, June 3rd, Grant Pickering sold 2,616 shares of Vaxcyte stock. The stock was sold at an average price of $72.06, for a total transaction of $188,508.96.
• On Thursday, May 23rd, Grant Pickering sold 15,000 shares of Vaxcyte stock. The stock was sold at an average price of $69.43, for a total transaction of $1,041,450.00.
• On Tuesday, April 23rd, Grant Pickering sold 15,000 shares of Vaxcyte stock. The shares were sold at an average price of $61.92, for a total transaction of $928,800.00.

Vaxcyte Stock Performance

Shares of PCVX opened at $76.26 on Thursday. Vaxcyte, Inc. has a fifty-two week low of $44.20 and a fifty-two week high of $82.04. The firm has a 50 day moving average price of $70.52 and a 200-day moving average price of $68.28.

Vaxcyte (NASDAQ:PCVX) last issued its earnings results on Wednesday, May 8th. The company reported ($0.85) EPS for the quarter, topping the consensus estimate of ($1.13) by $0.28. Equities analysts expect that Vaxcyte, Inc. will post -3.96 earnings per share for the current year.

Analysts Set New Price Targets

PCVX has been the subject of a number of research analyst reports. Cantor Fitzgerald restated an “overweight” rating on shares of Vaxcyte in a report on Thursday, June 20th. Needham & Company LLC reiterated a “buy” rating and set a $95.00 target price on shares of Vaxcyte in a research report on Friday, June 28th.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. Teachers Retirement System of The State of Kentucky increased its position in Vaxcyte by 16.6% during the 1st quarter. Teachers Retirement System of The State of Kentucky now owns 25,059 shares of the company’s stock valued at $1,712,000 after purchasing an additional 3,564 shares during the period. Farallon Capital Management LLC boosted its stake in Vaxcyte by 11,000.0% in the 1st quarter. Farallon Capital Management LLC now owns 377,400 shares of the company’s stock worth $25,780,000 after purchasing an additional 374,000 shares in the last quarter. RA Capital Management L.P. boosted its stake in Vaxcyte by 4.0% in the 1st quarter. RA Capital Management L.P. now owns 8,203,754 shares of the company’s stock worth $560,398,000 after purchasing an additional 312,500 shares in the last quarter. Tidal Investments LLC bought a new position in Vaxcyte in the 1st quarter worth about $405,000. Finally, California State Teachers Retirement System lifted its stake in Vaxcyte by 11.8% during the 1st quarter. California State Teachers Retirement System now owns 92,026 shares of the company’s stock valued at $6,286,000 after acquiring an additional 9,695 shares during the period. 96.78% of the stock is owned by hedge funds and other institutional investors.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.